Zbysek P.
- Country
- Czechia
- Department
- Neurologická klinika
Research Overview
- Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
- Phase 3 Randomized Trial of Human Normal Immunoglobulin to Prevent Infections in IgG‑deficient Patients with Autoimmune/Rheumatic Disease on B‑cell Depletion Therapy
- Phase 3 Randomized Double-Blind Study of Orelabrutinib for Primary Progressive Multiple Sclerosis in Patients With PPMS
Data & Insights
Has run more than one trial at 345 of 604 partner sites.
Specializations
Multiple Sclerosis Management
The investigator specializes in treating various forms of multiple sclerosis, with particular emphasis on both relapsing multiple sclerosis (RMS) and progressive multiple sclerosis (PMS). Their research involves evaluation of novel therapeutic approaches for managing MS symptoms and disease progression.
- Relapsing-Remitting MS
- Primary Progressive MS
- Secondary Progressive MS
Innovative Therapeutic Approaches
The investigator focuses on advancing treatment options through various therapeutic mechanisms, including BTK inhibitors and monoclonal antibodies. Their work encompasses both established and experimental treatments for neurological conditions.
- Novel Drug Formulations
- Long-term Treatment Safety
- Combination Therapies
Neurological Disorders
Beyond MS, the investigator's expertise extends to other neurological conditions, including myelin oligodendrocyte glycoprotein antibody-associated disease and autoimmune encephalitis. Their research encompasses both adult and pediatric populations.
- Chronic Migraine Management
- Autoimmune Neurological Conditions
- Pediatric Neurological Disorders
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.